대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	Serum hepcidin may be a uremic toxin: Results from the KoreaN Cohort Study for Outcomes in Patients with Chronic Kidney Disease (KNOW-CKD)
저자	Se-jin LEE, *Su ah SUNG, Sung woo LEE
출판정보	2017; 2017(1):
키워드	hepcidin, kidney function, erythropoietin stimulating agents, iron supplements, chronic kidney disease
초록	Objectives : This study aimed to investigate the related factors with serum hepcidin level in patients with non-dialysis chronic kidney disease (CKD). Methods : We used the baseline database of a large-scaled multicenter prospective cohort in Korea of 2,238 patients with non-dialysis CKD. After excluding patients with missing serum hepcidin and hemoglobin levels, the study included 2090 subjects. Results : Lower estimated glomerular filtration rate (eGFR) and hemoglobin level and higher levels of inflammatory markers and iron markers were independently associated with higher serum hepcidin level (Table 1). In a subgroup analysis, eGFR rate was inversely associated with serum hepcidin level, in patients with CKD stages 3b–5, but not in those with CKD stages 1–3a (Table 2). Iron supplements were associated with increased serum hepcidin level, in patients with CKD stages 1–3a, but not in those with CKD stages 3b–5. Use of erythropoietin stimulating agents was associated with increasing serum hepcidin level, in patients with CKD stages 3b–5, but not in those with CKD 1– 3a. Serum hepcidin level positively correlated with erythropoietin stimulating agent dosage (Figure 1). Conclusions : Reduced kidney function was associated with increased serum hepcidin levels, especially in patients with advanced CKD. Iron supplementation was positively correlated with serum hepcidin levels, especially in patients with early CKD. The higher hepcidin level in ESA users, particularly in those with advanced CKD, suggests that hepcidin is a key peptide in EPO resistance.
원문(PDF)	PDF 원문보기

목록

위로가기